wellrank.ai
Sign In
Alli logo

Alli

First cited by AI Jun 14, 2026
alliantcreditunion.com ↗

Surfaced organically in AI answers about glp-1 weight loss. Not yet profiled.

Alli is losing the AEO war.

Not cited in a single tracked AI answer since Oct 22, 2026, down from a peak of 17% visibility in glp-1 weight loss on Oct 1, 2026. This page stays public, and recovery shows here the day it happens.

AI Visibility

Visibility trend

GLP-1 weight loss, daily share of AI answers mentioning Alli, through Oct 27, 2026.

0.0%

Last cited Oct 22, 2026 · peak 17% on Oct 1

By engine

Where Alli is strong, and where it is invisible.

  • No engine data yet.

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 0 positive mentions
  • 20 neutral
  • 2 mixed or cautious

Recent AI answers mentioning Alli

ChatGPTOct 16, 2026, 11:30 UTC
What happens when I stop taking GLP-1s? Will I regain the weight?

Short answer: yes — if you stop a GLP‑1 (semaglutide, tirzepatide, etc.) most people will regain at least some — often much — of the weight they lost unless they replace the drug’s effect with strong, sustained lifestyle and/or other medical interventions. Stopping doesn’t permanently “reset” appetite or metabolism for most people; the drug’s appetite‑suppressing and metabolic effects wear off and hunger, food reward, and energy balance often revert. What typically happens after stopping Appetite and cravings usually increase. GLP‑1 drugs reduce hunger and food reward; when they’re stopped those signals typically return. Weight regain is common and can begin within weeks to months; many studies and clinical experience show substantial regain over 6–12 months if no other measures are taken. If you are taking the GLP‑1 for diabetes, stopping can raise blood glucose; you’ll need closer monitoring and possible adjustments of other diabetes medicines. Side effects that occurred while taking the drug (nausea, constipation) generally improve after stopping. If you plan pregnancy, GLP‑1s are usually stopped because fetal safety isn’t established. Why regain happens GLP‑1 drugs treat physiology (appetite, satiety, gastric emptying) but not always the behavioral, environmental, or biological drivers that led to weight gain in the first place. Metabolic adaptations to weight loss (lower resting energy expenditure, stronger hunger signals) persist and are unmasked when the drug is stopped. How to reduce or slow regain (practical steps) Don’t stop abruptly without a plan. Talk with your prescribing clinician first. If you have diabetes, glucose monitoring is essential. Work with a team: primary care or endocrinologist + registered dietitian (RD) experienced in weight management. RDs can teach meal plans, protein/fiber strategies, and appetite management. Nutrition & exercise: prioritize higher protein, fiber, and regular resistance training to preserve lean mass and resting metabolism. Aim for consistent meals and reduce liquid calories. Behavioral strategies: structured programs, cognitive behavioral therapy (CBT) for eating, and regular self‑monitoring (weight, food logs) help maintain loss. Consider pharmacologic maintenance: some people switch to or continue a lower‑dose GLP‑1 as maintenance or use another FDA‑approved obesity med (see options below). Discuss risks, benefits, and cost with your clinician. Regular follow‑up and early action if weight starts to creep back up (more intensive diet/physical activity or re‑starting meds) give the best chance to maintain loss. Medications and services you can discuss with your clinician GLP‑1s: Wegovy and Ozempic (semaglutide), Zepbound or Mounjaro (tirzepatide). These are effective for weight but most benefit is while you stay on them. Other FDA‑approved options for weight management: Saxenda (liraglutide), Qsymia (phentermine/topiramate), Contrave (bupropion/naltrexone), and orlistat (Xenical/Alli). These have different side effects and efficacy — your doctor can advise which might suit you. Behavioral programs: WW (Weight Watchers) or the CDC Diabetes Prevention Program (DPP) for structured lifestyle support. These provide regular coaching and accountability. Digital tools: Noom (behavioral/psychology focus), MyFitnessPal or Cronometer (tracking calories and protein). These help with self‑monitoring, which predicts better maintenance. Professional support: find a board‑certified obesity medicine specialist or endocrinologist, and a registered dietitian (look for “RD” or “RDN”). Many clinics offer multidisciplinary weight‑management programs. Questions to ask your clinician before stopping What will happen to my blood sugar/medications if I stop? Can we create a maintenance plan (diet, exercise, follow‑up schedule) before I stop? Are there alternative medications or a taper/transition strategy appropriate for me? What monitoring (weight, labs) should we do and how often? Bottom line Stopping a GLP‑1 commonly leads to increased appetite and weight regain unless you have a concrete, evidence‑based maintenance plan (behavioral program, diet/exercise, and/or alternative medication). Talk with your prescriber and a dietitian to create a personalized plan before you stop so you can maximize the chance of keeping your losses. If you want, tell me which medication you’re on and why you’re stopping (cost, side effects, pregnancy, etc.), and I can suggest a more specific transition plan and questions to take to your clinician.

Mentioned in position 9 of 13

Read full answer with sources →
ChatGPTOct 14, 2026, 11:30 UTC
I want to lose 30 pounds and diets have not worked. What are my options?

I’m glad you asked — losing 30 pounds is a big goal and there are several medically safe paths beyond “diets” alone. Which option is best depends on your BMI, health conditions, prior attempts, insurance and how you want to lose the weight. Below is a concise, practical rundown of evidence-based options, the common brand names, why they’re used, and what to do next. 1) Comprehensive lifestyle + behavioral programs (first-line for everyone) What: Structured plans with a registered dietitian (RD), behavior change/CBT, exercise plan and regular follow-up. Brands/services: WW (WeightWatchers) — widely available behavioral program; Noom — app-based cognitive behavioral approach; local medical weight-management clinics that include RDs and exercise specialists. Why: Support, accountability and behavior change improve long-term success compared with “do-it-yourself” diets. 2) Prescription medications for chronic weight management For many people with BMI ≥30 or ≥27 with weight-related conditions (hypertension, diabetes, sleep apnea), these can produce significant, sustained loss. GLP‑1 and GIP/GLP‑1 agonists: Wegovy (semaglutide) — approved specifically for weight loss; strong average weight loss in trials. Zepbound (tirzepatide) — newer option that has produced very large average weight loss in studies. (Related: Ozempic/Mounjaro are diabetes brands for the same/related drugs; dosing and indications differ.) Other FDA-approved meds: Qsymia (phentermine/topiramate) — stimulant + anticonvulsant combination helpful for many. Contrave (bupropion/naltrexone) — affects reward pathways and appetite. Xenical (orlistat) / Alli (OTC orlistat) — reduces fat absorption. Plenity (Gelesis) — prescription oral device (hydrogel) for BMI 25–40 to promote fullness. Why: These medications work on appetite, satiety and metabolism and often produce more weight loss than lifestyle alone. Side effects and costs vary; discuss with a clinician. 3) Endoscopic (non-surgical) options Intragastric balloons: Orbera (and similar devices) — placed endoscopically, left in stomach months to reduce volume and increase fullness. Endoscopic sleeve gastroplasty (ESG): Uses an endoscopic suturing device (e.g., Apollo OverStitch) to reduce stomach size without open surgery. Why: Less invasive than surgery, moderate weight loss, option for people not ready for surgery. 4) Bariatric (metabolic) surgery — most effective long-term for large weight loss Common procedures: Sleeve gastrectomy — removes a portion of the stomach. Roux-en-Y gastric bypass — reduces stomach size and changes absorption. Why: Produces the largest, most durable weight loss and often improves or resolves diabetes and other conditions. Typically considered for BMI ≥40, or BMI ≥35 with comorbidities (guidelines sometimes allow lower BMI for serious metabolic disease). Seek surgeons at MBSAQIP-accredited centers (e.g., major academic centers or accredited weight-loss centers). 5) Supportive medical care and evaluation (important before choosing a path) Get a medical evaluation: screen for thyroid disease, sleep apnea, diabetes, medications that cause weight gain, mental health issues, and readiness to change. Find specialists: primary care, an ABOM-certified obesity medicine specialist (search at American Board of Obesity Medicine), bariatric surgeons (MBSAQIP-accredited). Ask about insurance coverage—many insurers cover bariatric surgery and sometimes meds or programs; coverage for GLP‑1s varies. 6) What to avoid / be cautious about Unregulated supplements, “detox” cleanses, fad diets without medical supervision — often unsafe or ineffective. Very-low-calorie diets should only be done under medical supervision. Be aware of side effects and long-term commitment (some meds require ongoing use to maintain weight loss). Practical next steps I can help with Calculate your BMI if you tell me your height and weight. Draft questions to bring to your primary care or to an obesity clinic (e.g., medication options, surgical candidacy, costs/coverage). Help locate ABOM-certified obesity specialists or MBSAQIP-accredited bariatric centers nearby. If you want, tell me your current height, weight and any major medical conditions or medications and I’ll tailor recommendations (and calculate BMI) and suggest the most likely options for you.

Mentioned in position 5 of 8

Read full answer with sources →
ChatGPTOct 1, 2026, 11:30 UTC
What happens when I stop taking GLP-1s? Will I regain the weight?

Short answer: Yes — many people regain at least some or most of the weight when they stop GLP‑1 drugs unless they keep up strong lifestyle changes or switch to another long‑term strategy. GLP‑1s are powerful tools for lowering appetite and caloric intake, and stopping them usually lets appetite and food intake rise again. What’s happening physiologically GLP‑1 receptor agonists (semaglutide, tirzepatide, liraglutide, etc.) reduce appetite, increase satiety, slow gastric emptying and change food reward signals. When the drug is stopped those effects fade, so hunger returns and it’s easier to eat more. In addition, weight loss causes reduction in resting metabolic rate and hormonal changes (leptin/ghrelin etc.) that favor weight regain — these changes can persist after stopping the drug. What the evidence shows Clinical trials and follow‑up studies have repeatedly found that people tend to regain weight after discontinuing GLP‑1 therapy unless other measures are kept in place. For example, participants who stopped semaglutide in the STEP trials regained much of the lost weight over months to a year after stopping. Some people who adopt durable behavior changes (intensive dietary plans, exercise, cognitive/behavioral programs) keep a meaningful portion of their loss, but that’s less common than continued medication plus lifestyle support. Practical options if you plan to stop Plan the stop with your prescriber — sudden discontinuation doesn’t typically cause dangerous withdrawal, but appetite and GI symptoms can change and a plan helps. Intensify behavioral supports before/after stopping: meet with a registered dietitian, use structured programs (e.g., Diabetes Prevention Program, WW/WeightWatchers, Noom, local medical weight‑loss programs), and increase physical activity. Consider alternative or adjunct medications if appropriate: examples include other GLP‑1 or incretin agents (Wegovy or Ozempic — semaglutide; Saxenda — liraglutide; Mounjaro or Zepbound — tirzepatide), or non‑GLP options such as Contrave (naltrexone‑bupropion), Qsymia (phentermine/topiramate), or orlistat (Xenical/Alli). Your clinician can advise what’s best for your medical situation and goals. For some people, long‑term medication (just like long‑term treatment for hypertension or diabetes) is the most reliable way to maintain weight loss. When to talk to your clinician If you’re thinking about stopping because of side effects, cost, pregnancy planning, surgery, or other reasons — discuss it with the prescriber first. They can help taper if needed, suggest alternatives, and put a weight‑maintenance plan in place. If you want, tell me which GLP‑1 you're taking (brand or generic) and why you’re stopping (side effects, cost, pregnancy, finished program), and I can give more specific next‑step suggestions.

Mentioned in position 7 of 7

Read full answer with sources →
Google AISep 7, 2026, 16:44 UTC
My insurance denied Wegovy. Are compounded GLP-1s my best option?

It's completely understandable to feel frustrated when your insurance denies a medication like Wegovy, especially when you know it could be beneficial. While compounded GLP-1s might seem like a more accessible and affordable option, it's crucial to understand their pros and cons and explore all alternatives. Are Compounded GLP-1s Your Best Option? Not necessarily, and they come with significant caveats. Compounded medications are custom-made by a pharmacy for an individual patient based on a doctor's prescription. They are generally only intended for situations where an FDA-approved drug is unavailable, or a patient has specific needs (like an allergy to an inactive ingredient in the brand-name version). Here's a breakdown: Potential Downsides and Risks of Compounded GLP-1s: Not FDA-Approved: This is the biggest concern. Compounded drugs do not undergo the rigorous safety and efficacy testing that the FDA requires for brand-name medications like Wegovy. This means their quality, potency, and purity are not guaranteed. Safety Concerns: The FDA has issued strong warnings against compounded semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (the active ingredient in Zepbound and Mounjaro) due to reports of adverse events. Some compounded versions might use salt forms of the active ingredient, which are not the same as the active ingredients in the FDA-approved drugs. Lack of Oversight: There's less regulatory oversight for compounding pharmacies compared to pharmaceutical manufacturers. This can lead to variations in the quality of ingredients, manufacturing processes, and sterile conditions. Uncertain Efficacy: Since they haven't been through clinical trials, there's no guarantee that a compounded GLP-1 will work as effectively or predictably as the brand-name version. Legality/Availability: The ability to compound these drugs depends on the original FDA-approved drug being on the FDA's "drug shortage" list. When the shortage eases, compounding may become illegal. Why People Consider Compounded GLP-1s: Cost: They are often significantly cheaper than the brand-name versions, especially without insurance coverage. Accessibility: They offer an alternative when brand-name drugs are in short supply or denied by insurance. Before considering a compounded GLP-1, I strongly recommend exploring these other options: Appeal Your Insurance Denial: This is often the best first step. Work with your doctor to submit an appeal, providing medical documentation of your need for Wegovy, previous weight loss attempts, and any co-existing conditions. Sometimes, a detailed letter from your physician can make a difference. Explore Other FDA-Approved GLP-1 Medications for Weight Management: Zepbound (tirzepatide): This is the newest FDA-approved GLP-1 (and GIP) receptor agonist specifically for chronic weight management. It's often very effective, and your insurance might cover it even if they denied Wegovy. Saxenda (liraglutide): This is an older, daily injectable GLP-1 specifically approved for weight management. While it might be slightly less potent than Wegovy or Zepbound, it's a proven option. Ozempic (semaglutide for Type 2 Diabetes) or Mounjaro (tirzepatide for Type 2 Diabetes): While these are approved for Type 2 Diabetes, they are the same active ingredients as Wegovy and Zepbound. If you have Type 2 Diabetes, your insurance might cover them, and weight loss is a significant side effect. However, using them off-label solely for weight loss can be challenging for insurance coverage.* Explore Other FDA-Approved Weight Loss Medications (Non-GLP-1s): Contrave (bupropion/naltrexone): An oral medication that works on brain pathways to reduce appetite and cravings. Qsymia (phentermine/topiramate extended-release): An oral combination medication that suppresses appetite and increases feelings of fullness. Xenical (orlistat) / Alli (over-the-counter orlistat): Works by blocking the absorption of some fat in your diet. Phentermine: A stimulant used short-term (typically up to 12 weeks) for appetite suppression. Consider Bariatric Surgery: If you meet the criteria (BMI usually 35+ with co-morbidities or 40+ without), bariatric surgery is a highly effective, long-term weight loss solution often covered by insurance. Work with a Medical Weight Loss Specialist: A doctor specializing in obesity medicine can help you navigate insurance appeals, explore all FDA-approved options, and create a comprehensive plan that includes diet, exercise, and behavioral therapy. If you absolutely must consider a compounded GLP-1 (after exhausting all other options and in discussion with your doctor): Only obtain it from a licensed, reputable compounding pharmacy with a valid prescription from your doctor. Ask detailed questions about their sourcing of ingredients, quality control, and testing procedures. Avoid "med spas" or online pharmacies that offer these without proper medical consultation and oversight. Be fully aware of the risks and monitor for any unusual side effects. In summary, while compounded GLP-1s exist, they are generally not your "best option" due to significant safety and quality concerns. Your primary focus should be on appealing your insurance denial for Wegovy or exploring other FDA-approved medications like Zepbound or Saxenda with your doctor. Always consult with your healthcare provider to discuss the best and safest course of action for your individual health needs.

Mentioned in position 9 of 9

Read full answer with sources →
ChatGPTAug 28, 2026, 21:37 UTC
My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: usually no — compounded GLP‑1s are not the best first option for most people. Try appeal routes, manufacturer help, or FDA‑approved alternatives before using compounded products. If you’re still considering compounding, only do so after careful checks (see below). Why compounded GLP‑1s are risky Not FDA approved: potency, purity, sterility and stability aren’t guaranteed the way brand drugs are. Infection/contamination risk with injectable compounding (there have been serious outbreaks in the past). Insurance almost never covers compounded versions — you’ll likely pay out of pocket. Limited liability/support: no manufacturer safety program or established pharmacovigilance. What to try first (recommended actions) Appeal the denial Ask your prescriber to submit a prior‑authorization appeal or a peer‑to‑peer review. Provide clinical documentation (BMI, comorbidities, prior weight‑loss attempts, labs). Appeals are often successful. Check manufacturer assistance and copay programs Novo Nordisk (Wegovy) and Eli Lilly (Zepbound/Mounjaro) offer patient support, co‑pay savings or patient assistance programs that can substantially lower cost for eligible patients. Contact the company’s patient support line or your prescriber’s office to enroll. Ask about other FDA‑approved options Saxenda (liraglutide) — FDA‑approved for weight management (different dosing but established safety record). Zepbound (tirzepatide) and Mounjaro (tirzepatide) — tirzepatide is available from Eli Lilly; Zepbound is approved for chronic weight management (discuss availability/cost with prescriber). Ozempic (semaglutide) or Rybelsus (oral semaglutide) — approved for diabetes but sometimes used under clinician guidance; insurance coverage may differ. Non-GLP‑1 weight medications: Qsymia (phentermine/topiramate), Contrave (naltrexone/bupropion), Xenical/Alli (orlistat) — these may be better covered by insurance. Your clinician can recommend which alternative fits your medical profile. Look for lower legitimate prices Use price‑comparison/coupon services such as GoodRx to check retail savings. Specialty pharmacies (CVS Specialty, Accredo, Optum Specialty) may be able to help with access and prior‑auth navigation. Consider clinical trials Search clinicaltrials.gov for trials of GLP‑1 or tirzepatide weight‑loss studies — participants may receive medication at no cost. If you’re considering compounded GLP‑1s (only after exhausting other options) Only use a reputable, licensed compounding pharmacy that follows sterile USP <797> standards. Ask for: Evidence of state board licensure and sterile compounding certification. Certificate of analysis, lot testing, and expiration/stability data. Written info on sterility testing and storage/handling. Discuss risks with your prescriber and get written informed consent. Understand your insurer almost certainly won’t cover it. If you’d like, I can: Help draft an appeal/prior‑authorization letter your clinician can use (I can include the clinical points insurers typically want). Look up patient assistance/savings program phone numbers and links for Wegovy or Zepbound (tell me your country). Walk through what to ask a compounding pharmacy if you end up considering that route. Tell me which country you’re in and why Wegovy was denied (medical reason on the denial) and I’ll tailor the next steps.

Mentioned in position 11 of 15

Read full answer with sources →
Google AIAug 18, 2026, 12:42 UTC
My insurance denied Wegovy. Are compounded GLP-1s my best option?

I understand your frustration with the insurance denial for Wegovy. It's a common challenge many people face, and it naturally leads to exploring alternatives like compounded GLP-1s. Let's break down the options, starting with compounded versions and then exploring other legitimate avenues. Understanding Compounded GLP-1s Compounded GLP-1 medications, such as compounded semaglutide or tirzepatide, are not FDA-approved. This is a critical distinction to understand. Why are they available then? Compounding pharmacies are generally allowed to create custom medications when: There's a specific patient need (e.g., allergy to an inactive ingredient in a commercial drug). There's a shortage of an FDA-approved drug. Historically, there have been shortages of brand-name GLP-1s like Wegovy, which opened the door for compounding pharmacies to produce their versions. The FDA's Stance and Risks: The FDA has issued warnings about compounded GLP-1s for several reasons: Lack of Oversight: Compounded drugs do not undergo the rigorous safety, efficacy, and quality testing that FDA-approved drugs do. There's no guarantee of purity, potency, or sterility. Different Ingredients: Some compounded versions use different salt forms (e.g., semaglutide sodium instead of semaglutide base, which is in Wegovy). The safety and effectiveness of these alternative forms have not been established. Contamination Risk: Without strict manufacturing controls, there's a risk of contamination. Unknown Efficacy and Side Effects: You might not get the intended dosage, and the side effects could be unpredictable or more severe than with the brand-name drug. Legality: The FDA has sent cease and desist letters to some companies marketing unapproved compounded versions, especially those not sourcing the active ingredient correctly. If you consider compounded GLP-1s, extreme caution is advised. You must ensure you are getting them from a reputable, licensed compounding pharmacy with a valid prescription from a licensed medical professional. Ask the pharmacy about their sourcing, testing, and what exact form of the active ingredient they are using. Your Best Options (Before Compounding) Before resorting to compounded versions, which carry inherent risks, there are several legitimate and safer avenues to explore: Appeal Your Insurance Denial Work with Your Doctor: This is often your best first step. Your doctor can submit an appeal with additional documentation supporting the medical necessity of Wegovy for your specific health situation. Prior Authorization (PA): Sometimes, a denial is due to incomplete paperwork for a prior authorization. Ensure all criteria are met. Formulary Exceptions: Your doctor can request a formulary exception if Wegovy isn't on your plan's approved list, arguing that other covered medications are not appropriate for you. Explore Other FDA-Approved GLP-1s (if your insurance covers them) Your insurance might cover a different GLP-1 medication. Check your plan's formulary. Zepbound (tirzepatide): This is another FDA-approved medication specifically for weight loss. It's a dual GLP-1 and GIP receptor agonist, which works similarly but has a slightly different mechanism than semaglutide. Ask your doctor if this is an option and check your insurance coverage. Manufacturer Coupon: Eli Lilly, the maker of Zepbound, offers a savings card that can significantly reduce the cost if your insurance doesn't cover it or if you have a high deductible. Saxenda (liraglutide): This is an older, daily injectable GLP-1 that is* FDA-approved for weight loss. While it requires daily injections (vs. weekly for Wegovy/Zepbound), it might be covered by your insurance. Off-Label Prescribing (Less Likely for Insurance Coverage): Ozempic (semaglutide) and Mounjaro (tirzepatide): These are FDA-approved for Type 2 Diabetes but often prescribed off-label for weight loss. However, insurance is much less likely to cover them for weight loss unless you also have a Type 2 Diabetes diagnosis. Manufacturer Coupons: Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) also offer savings cards for their diabetes medications if you have a T2D diagnosis. Other FDA-Approved Weight Loss Medications There are other categories of prescription medications approved for weight management that work differently than GLP-1s: Contrave (naltrexone/bupropion): An oral medication that targets hunger and cravings. Qsymia (phentermine/topiramate): An oral combination medication that suppresses appetite and increases satiety. Phentermine: A stimulant-like medication typically used for short-term weight loss. Orlistat (Xenical, Alli): An oral medication that blocks some fat absorption. Discuss these options with your doctor to see if any are appropriate for you and covered by your insurance. Medical Weight Loss Programs & Lifestyle Changes Supervised Programs: Many clinics offer structured medical weight loss programs that include dietary counseling, exercise plans, and sometimes other medications, with professional oversight. Registered Dietitian: Working with a registered dietitian can provide personalized nutrition guidance. Bariatric Surgery: For individuals with significant obesity (BMI > 40 or > 35 with co-morbidities), bariatric surgery is a highly effective option that is often covered by insurance. Recommendation My strongest recommendation is to work closely with your primary care doctor or an obesity specialist to explore the above options in this order: Appeal your insurance denial for Wegovy. Provide all necessary medical documentation. Investigate coverage for other FDA-approved GLP-1s for weight loss, specifically Zepbound or Saxenda. Utilize manufacturer savings programs if available. Discuss other FDA-approved weight loss medications to see if they are a suitable alternative. Only after exhausting all FDA-approved prescription options and understanding the associated risks, should you consider a compounded GLP-1. If you do, ensure it's from a highly reputable, licensed compounding pharmacy with a prescription from your doctor, and that they can verify the source and purity of their active ingredient. Your health and safety are paramount. Always consult with your healthcare provider for personalized medical advice.

Mentioned in position 11 of 11

Read full answer with sources →

TL;DR

Alli is an over-the-counter orlistat-based weight loss aid sold under the GlaxoSmithKline consumer health lineage and now owned by Haleon. It ranks tenth in WellRank's GLP-1 weight loss AI answer index with 17 percent visibility, meaning AI engines occasionally surface it as a lower-cost, non-prescription alternative to newer injectable therapies, though the tone across its 20 indexed mentions is overwhelmingly neutral with no positively framed citations.

Company Overview

Alli is a consumer weight loss brand built around orlistat 60 mg, the only FDA-approved over-the-counter weight loss drug available in the United States. The brand originated under GlaxoSmithKline and later moved to Haleon following that company's consumer health spinoff. It is sold through retail pharmacies and major online retailers rather than through a direct telehealth or prescription channel.

Product Features

  • Alli orlistat 60 mg capsules, the sole FDA-approved OTC weight loss pill in the US
  • Starter kit with a meal plan and food journal guide
  • Refill packs available at varying capsule counts for ongoing use
  • MyAlliPlan online support program with diet and activity tracking tools
  • Fat blocker mechanism that inhibits roughly 25 percent of dietary fat absorption

Target Market

Alli targets overweight adults in the United States who have a BMI of 25 or above and want a non-prescription, pharmacy-accessible weight loss option. It is intended to complement a reduced-calorie, lower-fat diet rather than serve as a standalone treatment. The brand does not require a clinician visit, making it accessible to consumers who prefer to avoid the telehealth or prescription pathway.

Buyer Personas

  • A cost-conscious adult who wants an FDA-approved weight loss aid without a doctor's visit or insurance hurdle.
  • A consumer who has tried diet and exercise alone and wants incremental pharmacological support available at a local pharmacy.
  • Someone seeking a bridge option while waiting for access to a GLP-1 prescription drug or during a medication shortage, as noted in sources like medvidi.com's wegovy shortage guide.
  • An older or risk-averse shopper who prefers a long-established, non-injectable drug over newer biologics.

Funding & Performance

Alli is a consumer brand under Haleon plc, a publicly traded company listed on the London Stock Exchange. Specific revenue figures attributable to the Alli product line alone are not publicly disclosed.

Recent Developments

Alli has surfaced more frequently in AI-generated content as a low-cost alternative to GLP-1 drugs like Wegovy and Ozempic, partly driven by ongoing GLP-1 supply constraints. Comparison roundups on sites such as GoodRx's Wegovy alternatives guide and WeightWatchers' Ozempic alternatives overview regularly include it, which appears to sustain its AI answer presence despite the brand predating the GLP-1 era by many years.

Competitive Landscape

In WellRank's co-mention data, Alli appears alongside prescription drugs including Qsymia, Contrave, Xenical, Zepbound, and Saxenda, as well as program-based competitors like Noom and pharma giants Novo Nordisk and Eli Lilly. Its real competitive distinction is price and OTC accessibility rather than efficacy parity with GLP-1 agents. Sources such as SingleCare's Wegovy alternatives breakdown and Medical News Today's alternatives coverage position it as a budget or accessibility option rather than a clinical equivalent.

Alli vs the brands AI recommends alongside it

The real competitive set in GLP-1 weight loss: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Alli logo
AlliThis brand
–
0.0%
Noom logo
Noom

9 shared answers

#5
33.3%

Email me when overtakes Alli

One email the day the ranks flip. Nothing else.

User Sentiment

Across WellRank's 20 indexed AI mentions, Alli receives zero positively framed citations, 18 neutral mentions, and 2 mixed or cautious ones. This pattern reflects the broader public conversation: the drug is generally accepted as legitimate and FDA-approved, but AI engines and health publishers tend to flag its gastrointestinal side effects and modest efficacy compared to GLP-1 therapies. Guides such as The Rx Index's best Wegovy alternatives and Healthline's Wegovy alternative roundup include it factually without strong endorsement.

Pricing

Alli is sold over the counter and pricing varies by retailer, pack size, and promotional period. Exact current prices are not published by the brand centrally and fluctuate across pharmacy chains and online sellers, though it is widely understood to be significantly less expensive than branded GLP-1 prescription drugs.

Sources cited around Alli

The sites engines cite in answers mentioning this brand. Win these, win the answer.

Track Alli weekly

One email a week: rank moves, new competitors, and the answers that changed. No noise.

Work at Alli? Get your AI Visibility Audit.

See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.